While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...
4don MSN
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback